Full-Life Technologies Signed an Agreement to Acquire Focus-X Therapeutics to Advance Peptide-Focused Radiopharmaceutical Pipeline
Shots:
- Focus-X will receive an up front & is eligible to receive development, regulatory & sales-based milestones of ~$245M along with royalties. The acquisition is expected to close in Q1’23
- The acquisition will bolster Full-Life's pipeline with the addition of 2 compounds, incl. a lead with initial human data, a robust pipeline, and world-class peptide discovery capabilities & advance the compound into clinical development by using its EU-focused radiotechnology & development platform
- Focus-X's two compounds are currently in development i.e., PMSA-targeted peptide for mCRPC and NTSR1-targeted peptide for pancreatic cancer while the PMSA-targeted compound is currently undergoing an investigator-initiated imaging study
Ref: PRNewswire | Image: Focus-X Therapeutics
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
